Schmitt, Mark http://orcid.org/0000-0002-1493-1127
Ceteci, Fatih
Gupta, Jalaj
Pesic, Marina
Böttger, Tim W.
Nicolas, Adele M.
Kennel, Kilian B.
Engel, Esther
Schewe, Matthias
Callak Kirisözü, Asude
Petrocelli, Valentina
Dabiri, Yasamin
Varga, Julia
Ramakrishnan, Mallika
Karimova, Madina
Ablasser, Andrea http://orcid.org/0000-0002-8475-8999
Sato, Toshiro http://orcid.org/0000-0001-8353-8137
Arkan, Melek C.
de Sauvage, Frederic J.
Greten, Florian R. http://orcid.org/0000-0002-3928-6080
Article History
Received: 25 November 2019
Accepted: 7 October 2022
First Online: 16 November 2022
Competing interests
: M. Schmitt, J.G. and F.R.G. have filed a patent regarding the use of P2X4 inhibitors in combination with cytotoxic compounds. F.J.d.S. is an employee of Genentech and owns Roche shares. F.R.G. is a consultant for Amazentis, which is a company not related to this study. All other authors declare no competing interests.